Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sanofi Sets Sights on 2026 NIP Inclusion of RSV Drug Beyfortus in Japan
October 2, 2025
- Teijin, Australian CDMO Form Alliance for Cell and Gene Therapies in Asia-Pacific
October 2, 2025
- Fuji Pharma Seeks Dysmenorrhea Use for Nextstellis in Thailand
October 2, 2025
- Chugai’s PiaSky Now Available in Taiwan for PNH
October 2, 2025
- Takeda to Reevaluate Osaka Plasma Facility Plan as Costs Mount
October 1, 2025
- SSP to Roll Out Pharmacist Training Ahead of OTC Cialis Launch in Japan
October 1, 2025
- Heartseed, Novo Nordisk End Global Cell Therapy Pact
October 1, 2025
- Dalton Drops ASKA Stake Increase Plan, Slams Firm’s “Self-Preservation”
October 1, 2025
- Nxera Earns US$10 Million Milestone from AbbVie in Neurology Deal
October 1, 2025
- Santen, RemeGen Win China Filing Acceptance for RC28-E in DME
October 1, 2025
- Ono Files SK Bio’s Epilepsy Med Cenobamate in Japan
October 1, 2025
- Parexel Exec Says FDA Keeps Reviews on Track amid Staff Cuts, but Notes Leadership Drain
September 30, 2025
- China Approves Monthly IV Maintenance Dosing of Leqembi
September 30, 2025
- Enhertu Outperforms Kadcyla in PIII Breast Cancer Trial
September 30, 2025
- Alfresa, Hiroshima Univ. Hospital Begin Talks on SFTS Collaboration
September 30, 2025
- Industry Fears Trump’s MFN Drug Pricing Push Could Deepen Japan’s Lag and Loss
September 29, 2025
- Riken Genesis CDx Earns Japan Nod for Truqap Combo Therapy
September 29, 2025
- Meiji Rolls Out 2-Dose Vial of COVID-19 Vaccine Kostaive
September 29, 2025
- Mochida Sees Domestic Biosimilar Supply Gains in And Pharma Tie-Up
September 26, 2025
- Fujifilm Launches US$3.2 Billion Biologics Plant in North Carolina
September 26, 2025
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…